Literature DB >> 7772281

Complement-immunoglobulin interactions.

V D Miletic1, M M Frank.   

Abstract

Normal circulating immunoglobulin may control complement binding to targets and thereby the manifestations of autoimmune disease. Molecular analysis of IgG and IgM mutants suggests that C1q binding by IgG utilizes a core Glu-X-Lys-X-Lys motif (where X is any amino acid). Additional amino acids, particularly homologous proline residues at position 331 in IgG and 436 in IgM, appear critical for classical pathway initiation. Glycosylation of IgG heavy chain is important in C1q binding, as well as glycosylation of IgA heavy chain for alternative pathway initiation. Additional recent evidence suggests an important role for C3 in antigen presentation. The data also raise the possibility that C3 plays a significant role in the intracellular antigen processing pathway.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7772281     DOI: 10.1016/0952-7915(95)80027-1

Source DB:  PubMed          Journal:  Curr Opin Immunol        ISSN: 0952-7915            Impact factor:   7.486


  17 in total

1.  Hybridoma passage in vitro may result in reduced ability of antimannan antibody to protect against disseminated candidiasis.

Authors:  Hong Xin; Jim E Cutler
Journal:  Infect Immun       Date:  2006-07       Impact factor: 3.441

2.  Construction and analysis of variants of a polyvalent Lyme disease vaccine: approaches for improving the immune response to chimeric vaccinogens.

Authors:  Christopher G Earnhart; Richard T Marconi
Journal:  Vaccine       Date:  2007-01-17       Impact factor: 3.641

3.  Immune complex-like moieties in immunoglobulin for intravenous use (i.v.Ig) bind complement and enhance phagocytosis of human erythrocytes.

Authors:  H Shoham-Kessary; Y Naot; H Gershon
Journal:  Clin Exp Immunol       Date:  1998-07       Impact factor: 4.330

Review 4.  Heavy chain deposition disease: an overview.

Authors:  Yuji Oe; Jun Soma; Hiroshi Sato; Sadayoshi Ito
Journal:  Clin Exp Nephrol       Date:  2013-05-08       Impact factor: 2.801

5.  Roles of interferon-gamma and interleukin-4 in murine lupus.

Authors:  S L Peng; J Moslehi; J Craft
Journal:  J Clin Invest       Date:  1997-04-15       Impact factor: 14.808

6.  Pathogenesis of autoimmunity in alphabeta T cell-deficient lupus-prone mice.

Authors:  S L Peng; J Cappadona; J M McNiff; M P Madaio; M J Owen; A C Hayday; J Craft
Journal:  Clin Exp Immunol       Date:  1998-01       Impact factor: 4.330

7.  Intravenous immunoglobulin prevents experimental autoimmune myositis in SJL mice by reducing anti-myosin antibody and by blocking complement deposition.

Authors:  J Wada; N Shintani; K Kikutani; T Nakae; T Yamauchi; K Takechi
Journal:  Clin Exp Immunol       Date:  2001-05       Impact factor: 4.330

8.  Killing of Streptococcus pneumoniae by capsular polysaccharide-specific polymeric IgA, complement, and phagocytes.

Authors:  E N Janoff; C Fasching; J M Orenstein; J B Rubins; N L Opstad; A P Dalmasso
Journal:  J Clin Invest       Date:  1999-10       Impact factor: 14.808

9.  Characterization of complement C3, C4, and factor B molecules in human bile.

Authors:  K Sumiyoshi; A Andoh; Y Fujiyama; H Sakumoto; T Bamba
Journal:  J Gastroenterol       Date:  1997-04       Impact factor: 7.527

10.  Heavily isotype-dependent protective activities of human antibodies against vaccinia virus extracellular virion antigen B5.

Authors:  Mohammed Rafii-El-Idrissi Benhnia; Megan M McCausland; John Laudenslager; Steven W Granger; Sandra Rickert; Lilia Koriazova; Tomoyuki Tahara; Ralph T Kubo; Shinichiro Kato; Shane Crotty
Journal:  J Virol       Date:  2009-09-30       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.